SUMMARY

• Summarized below are real-world, retrospective, observational, descriptive cohort studies that evaluated TALVEY utilization patterns in adult patients with relapsed or refractory multiple myeloma (RRMM).^1,2 
  • Banerjee et al (2024)¹ evaluated the demographic and clinical characteristics, dosing practices, and clinical use scenarios among patients treated with TALVEY (N=141) from the Komodo Healthcare Map™ database spanning from August 9, 2023 to June 8, 2024.
  • Rodriguez et al (2024)² described real-world characteristics, step-up dosing (SUD) patterns, dosing schedules, and early safety and effectiveness data in patients with RRMM receiving TALVEY (N=92) from August 9, 2024 to March 31, 2024 using data from Loopback Analytics (formerly Acentrus).

Real-world data

Banerjee et al (2024)¹ presented a real-world, retrospective, observational, descriptive cohort study to understand the demographic and clinical characteristics, dosing practices, and clinical use scenarios among patients treated with TALVEY from the Komodo Healthcare Map™ database.

Study Design/Methods

• This study included patients with RRMM identified from the Komodo Healthcare Map™ database who received TALVEY between August 9, 2023 (United States approval date), and June 8, 2024 (last data cutoff date). See Figure: Study Design: Talquetamab Utilization Patterns and Dose Schedules.
• Eligibility criteria:
  • Patients aged ≥18 years with ≥1 diagnosis code for multiple myeloma (MM) any time prior to or on the index date and ≥1 medical or pharmacy claim for commercial TALVEY between August 9, 2023, and June 8, 2024.
  • Patients with triple-class-exposed RRMM (≥1 proteasome inhibitor, ≥1 immunomodulatory drug, and ≥1 anti-CD38 therapy).
• Exclusion criteria: Patients enrolled in clinical trials.

Results

Treatment Disposition, Baseline Characteristics, and Disease Characteristics

• A total of 141 patients treated with TALVEY were included in the study. Baseline characteristics are provided in the Table: Demographic and Clinical Characteristics. n
• A total of 84 patients (59.6%) had prior exposure to commercial B-cell maturation antigen (BCMA)-targeted therapy, and 78 patients (55.3%) reported prior exposure to T-cell-redirected therapies.

Utilization Patterns

• Most patients (n=130; 92.2%) received TALVEY as monotherapy. A relatively smaller number of patients (n=3; 2.1%) received TALVEY in combination regimens, including teclistamab or other therapies, with the combination medications initiated within 2 months of the index date.
• TALVEY served as a bridging therapy for a small proportion of patients, with 19 (13.5%) receiving TALVEY following apheresis and 4 (2.8%) receiving a chimeric antigen receptor T-cell infusion by the data cutoff. See Table: TALVEY Utilization as Monotherapy and Combination Therapy in Patients With RRMM and an Eligible TALVEY Claim.

Dosing Patterns

• Among patients on QW and Q2W dosing after SUD, 24 out of 83 patients (28.9%) switched to once every 4 week (Q4W) dosing or LFD, with a median time to switching of 4.7 months.
  • TALVEY dosing frequency among patients who received ≥3 treatment doses is presented in the Tables: Dosing Frequency at the End of Follow-up and Dosing Frequency at the End of Follow-up by Initial Dosing Schedule. A total of 12 of 58 (20.7%) patients initially on Q2W dosing switched to Q3W or LFD.

Rodriguez et al (2024)² presented real-world characteristics, SUD patterns, dosing schedules, and early safety and effectiveness data in patients with RRMM receiving TALVEY using data from Loopback Analytics (formerly Acentrus), an electronic medical records database.

Study Design/Methods

• A chart review was conducted to supplement information from structured data, representing the safety data analysis set. See Figure: Study Design: Talquetamab SUD Patterns.
• Eligibility criteria:
  • Patients who received TALVEY after Food and Drug Administration (FDA) approval
  • Patients with ≥2 diagnostic codes for MM, with ≥1 prior to the index date
  • Patients ≥18 years of age
  • Patients who had ≥6 months of clinical activity prior to the index date
  • Patients did not have clinical trial enrollment during SUD

Results

Treatment Disposition, Baseline Characteristics, and Disease Characteristics

• Overall, 92 patients with RRMM (median age, 69 years) were included in this study. See Table: Baseline Patient Characteristics.

Treatment Patterns

• TALVEY initiation dates are presented in Table: TALVEY Initiation Dates.
• During a median follow-up period of 3.4 months, 83.7% of patients had complete SUD data. Of these, 79.2% (n=61 out of 77) completed the SUD phase within 7 to 8 days, and the most common TALVEY SUD phase was Q2W (67.5%).
• In the TALVEY treatment phase, 57.1% of patients received ≥3 doses. Most patients were on a QW (11.9%) or Q2W (64.3%) dosing schedule at the end of follow-up. See Table: Dosing Frequency at the End of Follow-up by Initial Dosing Schedule for additional details.

Adverse Events

• Adverse events reported in patients receiving TALVEY are presented in Table: Adverse Events of Interest.

Physician-Reported Response

• At a median follow-up of 5.3 months, the ORR was 81.8% for all patients with an evaluable response. The ORR was 84.2% and 78.6% for patients with and without prior BCMA exposure, respectively.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 10 December 2024.